WOONSOCKET, R.I., July 30 /PRNewswire-FirstCall/ — MultiCell
Technologies, Inc. (OTC Bulletin Board: MCET) has launched a new
website with a fresh new look and updated information about
discovery technology platforms and lead drug candidates. It also
provides information to answer investors’ most common
questions.
“The new website is designed to inform our shareholders,
scientists and the public about the Company’s proprietary
therapeutic pipeline which could fill critical unmet medical
needs,” stated W. Gerald Newmin,
Chairman and CEO of MultiCell.
About MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is a clinical-stage
biopharmaceutical company developing novel therapeutics and
discovery tools to address unmet medical needs for treatment of
neurological disorders, hepatic disease and cancer.
MultiCell’s therapeutic development platform relies on patented
techniques to: (i) isolate, characterize and differentiate stem
cells from the human liver, or (ii) control the immune response at
transcriptional and translational levels through dsRNA-sensing
molecules such as Toll-like receptor (TLR), RIG-I-like receptor
(RLR), and MDA-5 signaling, or (iii) generate specific and potent
immunity against key tumor targets through a novel immunoglobulin
treatment, or (iv) modulate the noradrenaline-adrenaline
neurotransmitter pathway.
MultiCell’s drug candidates are in various stages of discovery
optimization, and preclinical and clinical development:
- MCT-125 is a Phase 2 therapeutic candidate for treatment of
fatigue in MS patients, which has demonstrated efficacy in a
138-patient Phase IIa clinical trial. - MCT-465 is
‘/>”/>
